



Page 1 of 16

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	<i>ATTACH 96 8/13/02</i>
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AE						
	AP						
	AS						
	AE						
	AF						
	AC						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
LH	AL1	EP 0 531 300, B1	03/17/1993	Europe	—	—	Yes No
20	AM1	EP 0 538 754 A2	04/28/1993	Europe	—	—	Yes No
20	AN1	WD 94/02633 A1	02/03/1994	WIPO	—	—	Yes No
20	AO1	WD 94/12631 A1	06/09/1994	WIPO	—	—	Yes No
20	AP1	WD 95/00851 A1	01/05/1995	WIPO	—	—	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
LH	AF	1	Breitz, H.B., et al., "Clinical Experience with Rhenium-186-Labeled Monoclonal Antibodies for Radioimmunotherapy: Results of Phase I Trials," <i>J. Nucl. Med.</i> 33:1099-1109, The Society of Nuclear Medicine (1992)
LH	AS	1	Breitz, H.B., et al., "Pharmacokinetics and Normal Organ Dosimetry Following Intraperitoneal Rhenium-186-Labeled Monoclonal Antibody," <i>J. Nucl. Med.</i> 36:754-761, The Society of Nuclear Medicine (May 1995)
LH	AT	1	Chatterjee, M.B. et al., "Idiotypic antibody immunotherapy of cancer," <i>Cancer Immunol. Immunother.</i> 38:75-82, Springer-Verlag (1994)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
----------	--------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 2 of 16


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AB2	AB2	WO 95/00658 A1	01/05/1995	WIPO			Yes No
AM							Yes No
AS							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
10	AE	2		Chaudhary V.K. et al., "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," Proc. Natl. Acad. Sci. USA 87:1066-1070, National Academy Press (1990)			
11	AS	2		Ermak, G., et al., "Restricted Patterns of CD44 Variant Exon Expression in Human Papillary Thyroid Carcinoma," Cancer Res. 56:1037-1042, American Association for Cancer Research (March 1996)			
12	AT	2		Fox, S.B., et al., "CD44 and cancer screening," Lancet 342:546-549, Williams & Wilkens (1993)			

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



Page 3 of 15

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIER et al.	
		FILING DATE January 23, 2002	GROUP 1042

U. S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AN							Yes No
AV							Yes No
AS							Yes No
AT							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
AF	AF	3	Fox, S.B., et al., "Normal Human Tissues, in Addition to Some Tumors, Express Multiple Different CD44 Isoforms," <i>Cancer Res.</i> 54:4539-4546, American Association for Cancer Research (1994)				
AS	AS	3	Friedrichs, K., et al., "CD44 Isoforms Correlate with Cellular Differentiation but not with Prognosis in Human Breast Cancer," <i>Cancer Res.</i> 55:5424-5435, American Association for Cancer Research (November 1995)				
AT	AT	3	Fujiwara, K., et al., "Expression of a Lymphocyte Adhesion Molecule (CD44) in Malignant Lymphomas: Relevance to Primary Site, Histological Subtype and Clinical Stage," <i>Acta Med. Okayama</i> 47:215-222, Okayama University Medical School (1993)				

EXAMINER		DATE CONSIDERED	2/2/04
----------	--	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 4 of 15

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U. S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
A1							
A2							
A3							
A4							
A5							
A6							
A7							
A8							
A9							
A10							
A11							
A12							
A13							
A14							
A15							
A16							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
A1							Yes No
A2							Yes No
A3							Yes No
A4							Yes No
A5							Yes No
A6							Yes No
A7							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>[Signature]</i>	AF	4	Ghaffari, S., et al., "Differentiation-Associated Changes in CD44 Isoform Expression During Normal Hematopoiesis and Their Alteration in Chronic Myeloid Leukemia," <i>Blood</i> 86:2976-2985, W.B. Saunders Company (October 1995)				
<i>[Signature]</i>	AS	4	Ginther, U., et al., "A New Variant of Glycoprotein CD44 Confers Metastatic Potential to Rat Carcinoma Cells. <i>Cell</i> 65:13-24, Cell Press (1991)				
<i>[Signature]</i>	AT	4	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> 275:1041-1042, American Association for the Advancement of Science (November 1997)				

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

AUG 13 2002

Page 5 of 16

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED
JULY 15 2002
TECH CENTER 1600/2902

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>WJ</i>	AE	<u>S</u>	Heider, K.-H., et al., "A Human Homologue of the Rat Metastasis-associated Variant of CD44 Is Expressed in Colorectal Carcinomas and Adenomatous Polyps," <i>J. Cell Biol.</i> 120:227-233, The Rockefeller University Press (1993)
<i>LS</i>	AS	<u>S</u>	Heider, K.-H., et al., "Expression of CD44 isoforms in human renal cell carcinomas," <i>Virchows Arch.</i> 428:267-273, Springer-Verlag (July 1996)
<i>WJ</i>	AT	<u>S</u>	Hofmann, M., et al., "CD44 Splice Variants Confer Metastatic Behavior in Rats: Homologous Sequences Are Expressed in Human Tumor Cell Lines," <i>Cancer Res.</i> 51:5292-5297, American Association for Cancer Research (1991)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 6 of 16

FORM PTC-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


<i>Horst</i>	AR	6	Horst, E., et al., "Expression of a Human Homing Receptor (CD44) in Lymphoid Malignancies and Related Stages of Lymphoid Development," Leukemia 4:383-389, Williams & Wilkins (1990)
<i>Horst</i>	AS	6	Horst, E., et al., "Adhesion Molecules in the Prognosis of Diffuse Large-Cell Lymphoma: Expression of a Lymphocyte Homing Receptor (CD44), LFA-1 (CD11a,1b), and ICAM-1 (CD54)," Leukemia 4:595-599, Williams & Wilkins (1990)
<i>Jackson</i>	AT	6	Jackson, D.G., et al., "Multiple Variants of the Human Lymphocyte Homing Receptor CD44 Generated by Insertions at a Single Site in the Extracellular Domain," J. Biol. Chem. 267:4732-4739, The American Society for Biochemistry and Molecular Biology, Inc. (1992)

EXAMINER

DATE CONSIDERED

2/2/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 7 of 16

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 21, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>HO</i>	AR	7	Jain, R.K., "Barriers to Drug Delivery in Solid Tumors," <i>Sci. Am.</i> 271:58-65, Scientific American, Inc. (1994)				
<i>WA</i>	AS	7	Jalkanen, S., et al., "Lymphocyte Homing and Clinical Behavior of Non-Hodgkin's Lymphoma," <i>J. Clin. Invest.</i> 87:1835-1840, The American Society for Clinical Investigation, Inc. (1991)				
<i>W</i>	AT	7	Juveid, M., et al., "Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, an Anti-CD22 Monoclonal Antibody," <i>Cancer Res. (Suppl.)</i> 55:5899s-5907s, American Association for Cancer Research (December 1995)				

EXAMINER	<i>MH</i>	DATE CONSIDERED	<i>2/2/07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 601. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



Page 8 of 16

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							


RECEIVED
AUG 15 2002
TECH CENTER 1642
USPTO

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AI							Yes No
AJ							Yes No
AK							Yes No
AL							Yes No
AM							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>b</i>	AF	E	Kaufmann, M., et al., "CD44 variant exon epitopes in primary breast cancer and length of survival," Lancet 345:615-619, The Lancet, Ltd. (March 1995)
<i>VN</i>	AS	E	Koopman, G., et al., "Activated Human Lymphocytes and Aggressive Non-Hodgkin's Lymphomas Express a Homologue of the Rat Metastasis-associated Variant of CD44," J. Exp. Med. 177:897-904, The Rockefeller University Press (1993)
<i>VW</i>	AT	E	Mackay, C.R. et al., "Expression and Modulation of CD44 Variant Isoforms in Humans," J. Cell. Biol. 124:71-82, The Rockefeller University Press (1994)

EXAMINER  DATE CONSIDERED *2/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 9 of 15

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AN							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
20	AF	g	Möller, P., et al., "Venular endothelium binding molecules CD44 and LECA4-1 in normal and malignant B-cell populations. A comparative study," <i>Virchows Arch. A. Pathol. Anat.</i> 421:305-313, Springer-Verlag (1992)				
22	AS	g	Mülder, J.-W.R., et al., "Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins," <i>Lancet</i> 344:1470-1472, The Lancet, Ltd. (1994)				
24	AT	g	Pals, S.T., et al., "Expression of Lymphocyte Homing Receptor as a Mechanism of Dissemination in Non-Hodgkin's Lymphoma," <i>Blood</i> 73:885-888, Grune & Stratton (1989)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP • 09. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
AUG 18 2002
TECH CENTER 1600/290

2/2/04



Page 10 of 16

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>WJH</i>	AF	<u>10</u>	Picker, L.J., et al., "Expression of Lymphocyte Homing Receptor Antigen in Non-Hodgkin's Lymphoma," Am. J. Pathol. 130:496-504, American Association of Pathologists (1988)				
<i>WJH</i>	AS	<u>10</u>	Press, O. W., et al., "Phase II trial of ¹³¹ I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas," Lancet 346:336-340, The Lancet, Ltd. (August 1995)				
<i>WJH</i>	AT	<u>10</u>	Quidri, S.M., et al., "Evaluation of Indium-111- and Yttrium-90-Labeled Linker-Immunoconjugates in Nude Mice and Dogs," J. Nucl. Med. 34:938-945, The Society of Nuclear Medicine, Inc. (1993)				

EXAMINER	<i>WJH</i>	DATE CONSIDERED	<i>26/10/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant..			



Page 11 of 15

INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642


U.S. PATENT DOCUMENTS							
EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
20	AR	11	Ristamäki, R., et al., "Serum CD44 in Malignant Lymphoma: An Association With Treatment Response," <i>Blood</i> 84:238-243, W.B. Saunders Company (1994)				
W	AS	11	Ristamäki, R., et al., "CD44v5 Expression in Non-Hodgkin's Lymphoma: an Association with Low Histological Grade and Poor Prognosis," <i>J. Pathol.</i> 176:259-267, John Wiley & Sons, Ltd. (July 1995)				
W	AT	11	Salles, G., et al., "Alternatively Spliced CD44 Transcripts in Diffuse Large-Cell Lymphomas: Characterization and Comparison With Normal Activated B Cells and Epithelial Malignancies," <i>Blood</i> 82:3539-3547, W.B. Saunders Company (1993)				

EXAMINER:	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
-----------	--------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 12 of 16

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
AUG 15 2002
1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


<i>BD</i>	AF	<u>12</u>	Savage, P., et al., "A recombinant single chain antibody interleukin-2 fusion protein," Br. J. Cancer 67:304-310, Macmillan Press, Ltd. (1993)
<i>BD</i>	AS	<u>12</u>	Screaton, G.R., et al., "Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons," Proc. Natl. Acad. Sci. USA 90:12160-12164, National Academy Press (1993)
<i>WJ</i>	AT	<u>12</u>	Screaton, G.R., et al., "The Identification of a New Alternative Exon with Highly Restricted Tissue Expression in Transcripts Encoding the Mouse Pgp-1 (CD44) Homing Receptor," J. Biol. Chem. 268:12235-12238, The American Society for Biochemistry and Molecular Biology, Inc. (1993)

EXAMINER

DATE CONSIDERED

2/2/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 13 of 16

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIFER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U.S. PATENT DOCUMENTS							
EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED

AUG 15 2002

TECH CENTER 1600/2500

FOREIGN PATENT DOCUMENTS							
EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>W</i>	AF	<u>12</u>	Seaver, S., "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought," <i>Genet. Eng. News</i> 14:10,21, Mary Ann Liebert, Inc. (1994)				
<i>W</i>	AS	<u>12</u>	Seiter, S., et al., "Prevention of Tumor Metastasis Formation by Anti-Variant CD-14," <i>J. Exp. Med.</i> 177:443-455, The Rockefeller University Press (1993)				
<i>W</i>	AT	<u>12</u>	Stamenkovic, I., et al., "A Lymphocyte Molecule Implicated in Lymph Node Homing Is a Member of the Cartilage Link Protein Family," <i>Cell</i> 56:1057-1062, Cell Press (1989)				

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
----------	--------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 14 of 16

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED
AUG 15 2002
TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>LW</i>	AR	14	Stauder, R., et al., "CD44 Variant Isoforms in Non-Hodgkin's Lymphoma: A New Independent Prognostic Factor," <i>Blood</i> 85:2885-2899, W.B. Saunders Company (May 1995)
<i>MW</i>	AS	14	Tanabe, K.K., et al., "Expression of CD44R1 adhesion molecule in colon carcinomas and metastases," <i>Lancet</i> 341:725-726, Williams & Wilkins (1993)
<i>WT</i>	AT	14	Terpe, H.-J., et al., "CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues," <i>Histochemistry</i> 101:79-89, Springer-Verlag (1994)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
----------	--------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 15 of 16

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1042

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED
TECH CENTER 1400
AUG 15 2002

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL2							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

W	AR	15	Thomas, G.D., et al., "Antibodies for tumour immunodetecting and methods for antibody radiolabelling," in <i>Antibodies. Volume II. A Practical Approach</i> , Volume II, Catty, D., ed., IRL Press, Oxford, UK, pp. 223-244 (1989)
VH	AS	15	Tölg, C., et al., "Splicing choice from ten variant exons establishes CD44 variability," <i>Nucl. Acids Res.</i> 21:1225-1229, Oxford University Press (1993)
W	AT	15	Vriesendorp, H.M. et al., "Review of Five Consecutive Studies of Radiolabeled Immunoglobulin Therapy in Hodgkin's Disease," <i>Cancer Res. (Suppl.)</i> 55:5888s-5892s, American Association for Cancer Research (December 1995)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>2/2/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



Page 16 of 16

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.1910001/EKS/PSC

APPLICATION NO.
10/052,641

APPLICANT
HEIDER et al.

FILING DATE
January 23, 2002

GROUP
1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED
AUG 15 2002
TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Dialog File 351, Accession No. 91-340908/199147, Derwent WPI English language abstract for EP 0 531 300 B1 (Document AL1)
	AS	<u>16</u>	Dialog File 351, Accession No. 93-136002/199317, Derwent WPI English language abstract for EP 0 538 754 A2 (Document AM1)
	AT	<u>16</u>	Dialog File 351, Accession No. 95-052230/199507, Derwent WPI English language abstract for WO 95/00851 (Document AP1)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.